grant

The ALS Multidisciplinary Clinic at the University of Cincinnati Gardner Neuroscience Institute in Ohio has been gifted $13.5 million to advance its research and patient care initiatives related to amyotrophic lateral sclerosis (ALS). The donation comes from the estate of Hugh H. Hoffman, who earned a degree from the…

Coave Therapeutics has received a grant from the ALS Association to support the development of its gene therapy candidate CTx-TFEB for amyotrophic lateral sclerosis (ALS). The grant, made through the Lawrence and Isabel Barnett Drug Development Program, is part of the $2.9 million the ALS Association…

Myrobalan Therapeutics will use a $400,000 grant from the ALS Association — along with $24 million in new financing — to help advance the development of its oral CSF1 receptor (CSF-1R) inhibitor program, intended to reduce neuroinflammation and promote nerve repair in people with amyotrophic lateral sclerosis…

Dewpoint Therapeutics has received a grant from the Target ALS Foundation to advance the development of small molecules called c-mods, which will target the TDP-43 condensates thought to drive most cases of amyotrophic lateral sclerosis (ALS). Condensates are borderless compartments in cells that can cause cellular processes…

The ALS Association has given Oryzon Genomics nearly $500,000 to advance ORY-4001, a potential treatment of amyotrophic lateral sclerosis (ALS), into preclinical studies. The $498,690 grant was provided via the association’s Lawrence and Isabel Barnett Drug Development Program. Oryzon intends for laboratory studies in mouse disease models…

A new two-year, $400,000 grant will support studies — by EverythingALS and the Sean M. Healey and AMG Center for ALS at Massachusetts General Hospital (MGH) — aimed at identifying early digital diagnostic markers in amyotrophic lateral sclerosis (ALS). The award, from ALS Finding a Cure…

A new €2.5 million (about $2.5 million) grant from the European Union (EU) will help advance a prototype vaccine for amyotrophic lateral sclerosis (ALS) associated with mutations in the C9orf72 gene — its most common genetic cause. The European Innovation Council EIC Transition Grant will be used to further develop the vaccine,…

The U.S. Department of Defense (DOD) has awarded a $1.475 million grant to Aclipse Therapeutics to advance M102 — an experimental oral therapy for amyotrophic lateral sclerosis (ALS) — into first-in-human clinical trials. The therapeutic development award comes from the Congressionally Directed Medical Research Programs (CDMRP) at the…

A research team in Canada received a CA$1.6 million (almost $1.25 million) grant from the Weston Family Foundation to study the benefits of a specific probiotic in people with amyotrophic lateral sclerosis (ALS). Probiotics — found in yogurt, fermented foods, and dietary supplements — are live microorganisms thought to improve…

Amarna Therapeutics and Redoxis have received an €800,000 (about $900,000) grant from Eureka Eurostars to advance their joint project, ALPHAVAC, which aims to discover immune-related therapeutic targets of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Promising targets, initially focused on ALS, then will be used to…